

# Synthesis and Pharmacology Evolution of New Coumarin Clubbed Carbamodithioate Moiety using Biocatalyst

KEYURKUMAR A. KAMANI and KANUPRASAD D. PATEL\*

V. P. & R. P. T. P. Science College, Sardar Patel University,  
Vallabh Vidyanagar-388 120, Gujarat, India  
*keyurkamani28@gmail.com; drkdpatel64@yahoo.co.in*

Received 25 July 2016 / Accepted 3 September 2016

**Abstract:** A series of structurally new coumarin clubbed carbamodithioate derivatives **7a-t** were designed and synthesized by multistep synthesis using biocatalyst Baker's Yeast. All the new compounds were characterized by mass, <sup>1</sup>H and <sup>13</sup>C NMR and elemental analysis. Furthermore, compound **7a-t** evaluated for their *in vitro* antibacterial and antitubercular activities. The results indicated that some of the synthesized compounds possess promising antimicrobial activity against some gram-positive and gram-negative bacteria. Some compounds displayed good activity against *Mycobacterium tuberculosis H37 Rv* as compared to standard drug.

**Keywords:** Baker's yeast, Carbamodithioate, Coumarin, Antibacterial activity, Antitubercular activity

## Introduction

Biocatalyst has attracted the attention of organic as well as medical chemist for their selectivity and various organic transformations and baker's yeast prove itself useful in organic as well as medicinal chemistry<sup>1</sup>. Definitely we can say that most of natural product and widely distributed pharmaceutical agents contain sulphur as heteroatom in heterocyclic structure. Carbamodithioate are such heterocyclic system which is found to have interesting chemistry and wide utility<sup>2</sup>.

Drug design and development provide useful guidance to club various active moiety to achieve active molecule which is called pharmacophore hybridisation<sup>3</sup>. On this basis we made an attempt to synthesis and pharmacology evolution of new coumarin clubbed carbamodithioate moiety using biocatalyst. Coumarin and carbamodithioate are clubbed in a way to get desired molecule to obtain best result and it is mentioned here.

## Experimental

All the melting points were taken in scientific melting point apparatus and was uncorrected. Silica gel-G coated aluminum plates (Merck) were used to check purity and completion of

the reaction and spots were visualized by exposing the dry plates in iodine vapours as well as UV light used for it. Mass spectra of intermediates and final products were scanned on a Shimadzu LCMS 2010 spectrometer.  $^1\text{H}$  &  $^{13}\text{C}$  NMR spectra on a Bruker's WM 400 FT MHz NMR instrument using DMSO- $d_6$  as solvent and TMS as internal reference (chemical shifts in  $\delta$  ppm). The elemental analysis (C, H and N) of compounds was performed on Carlo Erba-1108 elemental analyzer.

#### General procedure of synthesis of carbamodithioate derivatives (7a-t)

In the round bottom flask, a mixture of **5a-t** (0.069 mol) and **6** (0.069 mol) was dissolved into the ethanol (25 mL) and allowed to reflux for 6–8 h. Solid product obtained as precipitate in reaction mass was checked by TLC and confirmed the formation of compound **7a-t**. In work up process, excess ethanol was removed by distillation, solid residue was treated with cold water, filtered, dried and purification was achieved by crystallization in ethanol to obtain pure compound **7a-t** (Table 1). Detailed characterisation of series **7a-t** given below

**Table 1.** Physical data and information of substitution of **7a-t**

S. No.	Compound	R	R <sub>1</sub>	% Yield	Mp, °C
1	<b>7a</b>	H	H	75	155
2	<b>7b</b>	H	NO <sub>2</sub>	80	142
3	<b>7c</b>	H	Cl	80	140
4	<b>7d</b>	H	F	85	132
5	<b>7e</b>	Cl	H	70	158
6	<b>7f</b>	Cl	NO <sub>2</sub>	95	168
7	<b>7g</b>	Cl	Cl	75	170
8	<b>7h</b>	Cl	F	78	121
9	<b>7i</b>	Br	H	84	135
10	<b>7j</b>	Br	NO <sub>2</sub>	80	140
11	<b>7k</b>	Br	Cl	90	169
12	<b>7l</b>	Br	F	92	147
13	<b>7m</b>	F	H	89	158
14	<b>7n</b>	F	NO <sub>2</sub>	78	135
15	<b>7o</b>	F	Cl	76	159
16	<b>7p</b>	F	F	90	148
17	<b>7q</b>	Me	H	92	151
18	<b>7r</b>	Me	NO <sub>2</sub>	90	130
19	<b>7s</b>	Me	Cl	95	124
20	<b>7t</b>	Me	F	60	145

#### 2-Oxo-2-(2-oxo-2H-chromen-3-yl)ethyl benzyl(phenyl)carbamodithioate (7a)

Chemical Formula: C<sub>25</sub>H<sub>19</sub>NO<sub>3</sub>S<sub>2</sub> MS ( $m/z$ ): 445.51 [M<sup>+</sup>].  $^1\text{H}$  NMR (400 MHz, DMSO)  $\delta$  8.32 (m, 1H), 7.49 (m, 1H), 7.51-6.56 (m, 13H), 4.91 (s, 2H), 4.20 (s, 2H).  $^{13}\text{C}$  NMR  $\delta$  193.03, 160.25, 154.11, 142.22, 137.12, 132.72, 129.45, 128.24, 128.67, 128.12, 126.50, 125.05, 120.51, 118.23, 117.87, 55.86, 42.53. Elemental Analysis: calculated C, 67.39; H, 4.30; N, 3.14% found C, 67.34; H, 4.37; N, 3.06%.

#### 2-Oxo-2-(2-oxo-2H-chromen-3-yl)ethyl (4-nitrobenzyl)(phenyl)carbamodithioate (7b)

Chemical Formula: C<sub>25</sub>H<sub>18</sub>N<sub>2</sub>O<sub>5</sub>S<sub>2</sub> MS ( $m/z$ ): 490.52 [M<sup>+</sup>].  $^1\text{H}$  NMR (400 MHz, DMSO)  $\delta$  8.22-6.98 (m, 14H), 5.15 (s, 2H), 4.46 (s, 2H).  $^{13}\text{C}$  NMR  $\delta$  193.06, 160.64, 154.24, 147.26,

143.64, 142.28, 132.69, 129.25, 128.55, 127.63, 126.55, 125.12, 123.59, 120.54, 118.12, 117.47, 53.75, 41.52. Elemental Analysis: calculated C, 61.21; H, 3.70; N, 5.71% found C, 61.12; H, 3.78; N, 5.82%.

*2-Oxo-2-(2-oxo-2H-chromen-3-yl)ethyl (4-chlorobenzyl)(phenyl) carbamodithioate(7c)*

Chemical Formula: C<sub>25</sub>H<sub>18</sub>ClNO<sub>3</sub>S<sub>2</sub> MS (*m/z*): 479.94 [M<sup>+</sup>]. <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.19-7.05 (m, 14H), 5.21 (s, 2H), 4.43 (s, 2H). <sup>13</sup>C NMR δ 193.25, 160.54, 154.54, 142.27, 135.06, 132.64, 130.54, 129.45, 128.84, 127.15, 126.21, 125.18, 120.52, 118.15, 117.25, 53.26, 41.92. Elemental Analysis: calculated C, 62.56; H, 3.78; N, 2.92% found C, 62.49; H, 3.86; N, 2.99%.

*2-Oxo-2-(2-oxo-2H-chromen-3-yl)ethyl (4-fluorobenzyl)(phenyl) carbamodithioate(7d)*

Chemical Formula: C<sub>25</sub>H<sub>18</sub>FNO<sub>3</sub>S<sub>2</sub> MS (*m/z*): 463.57 [M<sup>+</sup>]. <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.21-6.92 (m, 14H), 5.08 (s, 2H), 4.36 (s, 2H). <sup>13</sup>C NMR δ 194.01, 164.26, 161.64, 160.94, 154.13, 142.17, 132.87, 131.50, 130.61, 129.56, 127.85, 126.54, 125.18, 120.55, 118.68, 117.19, 115.74, 114.47, 53.83, 42.57. Elemental Analysis: calculated C, 64.78; H, 3.91; N, 3.02% found C, 64.83; H, 3.84; N, 3.13%.

*2-Oxo-2-(2-oxo-2H-chromen-3-yl)ethyl benzyl(4-chlorophenyl)carbamodithioate(7e)*

Chemical Formula: C<sub>25</sub>H<sub>18</sub>ClNO<sub>3</sub>S<sub>2</sub> MS (*m/z*): 479.93 [M<sup>+</sup>]. <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.29-6.96 (m, 14H), 5.20 (s, 2H), 4.32 (s, 2H). <sup>13</sup>C NMR δ 193.26, 160.71, 154.97, 140.67, 137.84, 132.57, 132.28, 129.62, 128.69, 128.22, 127.34, 127.17, 125.21, 120.26, 118.57, 117.58, 52.68, 42.59. Elemental Analysis: calculated C, 62.56; H, 3.78; N, 2.92% found C, 62.67; H, 3.84; N, 2.87%.

*2-Oxo-2-(2-oxo-2H-chromen-3-yl)ethyl (4-chlorophenyl)(4-nitrobenzyl) carbamodithioate(7f)*

Chemical Formula: C<sub>25</sub>H<sub>17</sub>ClN<sub>2</sub>O<sub>5</sub>S<sub>2</sub> MS (*m/z*): 524.95 [M<sup>+</sup>]. <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.37-6.99 (m, 13H), 5.02 (s, 2H), 4.33 (s, 2H). <sup>13</sup>C NMR δ 193.80, 160.69, 154.22, 147.50, 143.99, 140.82, 132.64, 132.38, 129.57, 128.86, 128.38, 127.65, 125.24, 123.73, 120.58, 118.85, 117.12, 53.87, 41.57. Elemental Analysis: calculated C, 57.20; H, 3.26; N, 5.34% found C, 57.29; H, 3.18; N, 5.42%.

*2-Oxo-2-(2-oxo-2H-chromen-3-yl)ethyl (4-chlorobenzyl)(4-chlorophenyl) carbamodithioate(7g)*

Chemical Formula: C<sub>25</sub>H<sub>17</sub>Cl<sub>2</sub>NO<sub>3</sub>S<sub>2</sub> MS (*m/z*): 514.41 [M<sup>+</sup>]. <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.34-6.04 (m, 13H), 5.18 (s, 2H), 4.28 (s, 2H). <sup>13</sup>C NMR δ 193.66, 160.82, 154.36, 140.67, 135.18, 133.08, 132.39, 130.27, 129.52, 128.96, 128.23, 127.17, 125.15, 120.26, 118.89, 117.25, 56.12, 42.81. Elemental Analysis: calculated C, 58.37; H, 3.33; N, 2.72% found C, 58.28; H, 3.41; N, 2.62%.

*2-Oxo-2-(2-oxo-2H-chromen-3-yl)ethyl (4-chlorophenyl)(4-fluorobenzyl) carbamodithioate(7h)*

Chemical Formula: C<sub>25</sub>H<sub>17</sub>ClFNO<sub>3</sub>S<sub>2</sub> MS (*m/z*): 497.92 [M<sup>+</sup>]. <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.18-6.91 (m, 13H), 5.07 (s, 2H), 4.41 (s, 2H). <sup>13</sup>C NMR δ 193.61, 164.78, 161.22, 160.64, 154.15, 140.24, 133.17, 132.89, 131.59, 130.68, 129.43, 128.29, 127.12, 125.39, 120.73, 118.38, 117.35, 115.19, 114.65, 55.64, 42.34. Elemental Analysis: calculated C, 60.30; H, 3.44; N, 2.81% found C, 60.41; H, 3.39; N, 2.87%.

*2-Oxo-2-(2-oxo-2H-chromen-3-yl)ethyl benzyl(4-bromophenyl)carbamdithioate(7i)*

Chemical Formula:  $C_{25}H_{18}BrNO_3S_2$  MS ( $m/z$ ): 524.48 [ $M^+$ ].  $^1H$  NMR (400 MHz, DMSO)  $\delta$  8.19-6.99 (m, 14H), 5.05 (s, 2H), 4.27 (s, 2H).  $^{13}C$  NMR  $\delta$  193.23, 160.56, 154.38, 141.33, 137.34, 132.74, 131.13, 129.64, 128.98, 128.86, 128.14, 126.78, 125.15, 120.38, 118.98, 118.26, 117.68, 54.57, 43.69. Elemental Analysis: calculated C, 57.26; H, 3.46; N, 2.67% found C, 57.32; H, 3.33; N, 2.74%.

*2-Oxo-2-(2-oxo-2H-chromen-3-yl)ethyl (4-bromophenyl)(4-nitrobenzyl)carbamdithioate(7j)*

Chemical Formula:  $C_{25}H_{17}BrN_2O_5S_2$  MS ( $m/z$ ): 569.44 [ $M^+$ ].  $^1H$  NMR (400 MHz, DMSO)  $\delta$  8.34-7.04 (m, 13H), 5.01 (s, 2H), 4.31 (s, 2H).  $^{13}C$  NMR  $\delta$  193.32, 160.62, 154.26, 147.26, 143.64, 141.16, 132.72, 131.22, 129.43, 128.87, 128.16, 126.58, 125.27, 123.75, 120.78, 118.66, 118.11, 117.34, 55.17, 44.14. Elemental Analysis: calculated C, 52.73; H, 3.01; N, 4.92% found C, 52.62; H, 3.13; N, 4.81%.

*2-Oxo-2-(2-oxo-2H-chromen-3-yl)ethyl (4-bromophenyl)(4-chlorobenzyl)carbamdithioate(7k)*

Chemical Formula:  $C_{25}H_{17}BrClNO_3S_2$  MS ( $m/z$ ): 558.84 [ $M^+$ ].  $^1H$  NMR (400 MHz, DMSO)  $\delta$  8.35-6.97 (m, 13H), 5.11 (s, 2H), 4.38 (s, 2H).  $^{13}C$  NMR  $\delta$  193.66, 160.70, 154.31, 141.26, 135.17, 132.92, 131.28, 130.15, 129.52, 128.89, 128.12, 126.77, 125.18, 120.58, 118.63, 118.13, 117.36, 55.69, 41.35. Elemental Analysis: calculated C, 53.73; H, 3.07; N, 2.51% found C, 53.68; H, 3.16; N, 2.43%.

*2-Oxo-2-(2-oxo-2H-chromen-3-yl)ethyl (4-bromophenyl)(4-fluorobenzyl)carbamdithioate(7l)*

Chemical Formula:  $C_{25}H_{17}BrFNO_3S_2$  MS ( $m/z$ ): 542.48 [ $M^+$ ].  $^1H$  NMR (400 MHz, DMSO)  $\delta$  8.20-6.91 (m, 13H), 5.18 (s, 2H), 4.39 (s, 2H).  $^{13}C$  NMR  $\delta$  193.34, 164.68, 161.74, 160.50, 154.36, 141.16, 132.83, 131.58, 131.36, 130.78, 129.25, 128.12, 126.66, 125.35, 120.66, 118.40, 118.26, 117.12, 115.54, 114.38, 56.71, 43.37. Elemental Analysis: calculated C, 55.36; H, 3.16; N, 2.58% found C, 55.28; H, 3.22; N, 2.42%.

*2-Oxo-2-(2-oxo-2H-chromen-3-yl)ethyl benzyl(4-fluorophenyl)carbamdithioate(7m)*

Chemical Formula:  $C_{25}H_{18}FNO_3S_2$  MS ( $m/z$ ): 463.57 [ $M^+$ ].  $^1H$  NMR (400 MHz, DMSO)  $\delta$  8.31-6.96 (m, 14H), 5.01 (s, 2H), 4.37 (s, 2H).  $^{13}C$  NMR  $\delta$  193.91, 164.48, 161.74, 160.22, 154.25, 139.50, 137.57, 132.64, 129.65, 128.96, 128.75, 128.15, 127.54, 125.21, 120.57, 118.11, 117.58, 116.66, 115.50, 54.84, 42.55. Elemental Analysis: calculated C, 64.78; H, 3.91; N, 3.02% found C, 64.84; H, 3.82; N, 3.11%.

*2-Oxo-2-(2-oxo-2H-chromen-3-yl)ethyl (4-fluorophenyl)(4-nitrobenzyl)carbamdithioate(7n)*

Chemical Formula:  $C_{25}H_{17}FN_2O_5S_2$  MS ( $m/z$ ): 508.56 [ $M^+$ ].  $^1H$  NMR (400 MHz, DMSO)  $\delta$  8.14-6.95 (m, 13H), 5.13 (s, 2H), 4.40 (s, 2H).  $^{13}C$  NMR  $\delta$  193.67, 164.43, 161.92, 160.67, 154.27, 147.24, 143.49, 139.71, 132.57, 129.69, 128.87, 128.15, 127.68, 125.12, 123.63, 120.57, 118.52, 117.47, 116.24, 115.54, 53.38, 43.57. Elemental Analysis: calculated C, 59.05; H, 3.37; N, 5.51% found C, 59.16; H, 3.46; N, 5.42%.

*2-Oxo-2-(2-oxo-2H-chromen-3-yl)ethyl (4-chlorobenzyl)(4-fluorophenyl) carbamodithioate(7o)*

Chemical Formula: C<sub>25</sub>H<sub>17</sub>ClFNO<sub>3</sub>S<sub>2</sub> MS (*m/z*): 497.94 [M<sup>+</sup>]. <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.08-6.97 (m, 13H), 5.06 (s, 2H), 4.39 (s, 2H). <sup>13</sup>C NMR δ 193.86, 164.47, 161.82, 160.66, 154.44, 139.52, 135.17, 132.43, 130.65, 129.41, 128.64, 128.18, 127.68, 125.20, 120.71, 118.54, 117.48, 116.25, 115.87, 55.68, 41.64. Elemental Analysis: calculated C, 60.30; H, 3.44; N, 2.81% found C, 60.28; H, 3.57; N, 2.92%.

*2-Oxo-2-(2-oxo-2H-chromen-3-yl)ethyl (4-fluorobenzyl)(4-fluorophenyl) carbamodithioate(7p)*

Chemical Formula: C<sub>25</sub>H<sub>17</sub>F<sub>2</sub>NO<sub>3</sub>S<sub>2</sub> MS (*m/z*): 481.53 [M<sup>+</sup>]. <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.31-6.93 (m, 13H), 5.09 (s, 2H), 4.37 (s, 2H). <sup>13</sup>C NMR δ 193.68, 164.87, 164.36, 161.93, 161.52, 160.86, 154.15, 139.59, 132.90, 131.41, 130.82, 129.59, 128.19, 127.64, 125.15, 120.83, 118.66, 117.27, 116.51, 115.98, 115.65, 114.64, 53.87, 42.22. Elemental Analysis: calculated C, 62.36; H, 3.56; N, 2.91% found C, 62.41; H, 3.48; N, 2.97%.

*2-Oxo-2-(2-oxo-2H-chromen-3-yl)ethyl benzyl(p-tolyl)carbamodithioate(7q)*

Chemical Formula: C<sub>26</sub>H<sub>21</sub>NO<sub>3</sub>S<sub>2</sub> MS (*m/z*): 459.54 [M<sup>+</sup>]. <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.19-6.90 (m, 14H), 5.16 (s, 2H), 4.32 (s, 2H) 2.24 (s, 3H). <sup>13</sup>C NMR δ 193.78, 160.85, 154.23, 140.53, 137.24, 136.56, 132.75, 129.45, 128.96, 128.72, 128.12, 125.18, 122.52, 120.69, 118.22, 117.12, 55.67, 42.53, 23.15. Elemental Analysis: calculated C, 67.95; H, 4.61; N, 3.05% found C, 67.83; H, 4.55; N, 3.19%.

*2-Oxo-2-(2-oxo-2H-chromen-3-yl)ethyl (4-nitrobenzyl)(p-tolyl)carbamodithioate(7r)*

Chemical Formula: C<sub>26</sub>H<sub>20</sub>N<sub>2</sub>O<sub>5</sub>S<sub>2</sub> MS (*m/z*): 504.53 [M<sup>+</sup>]. <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.21-6.93 (m, 13H), 5.18 (s, 2H), 4.37 (s, 2H) 2.29 (s, 3H). <sup>13</sup>C NMR δ 193.89, 160.67, 154.50, 147.34, 143.52, 140.49, 136.68, 132.82, 129.78, 128.62, 128.17, 125.24, 123.87, 122.58, 120.70, 118.23, 117.19, 55.67, 42.58, 22.92. Elemental Analysis: calculated C, 61.89; H, 4.00; N, 5.55% found C, 61.96; H, 4.12; N, 5.42%.

*2-Oxo-2-(2-oxo-2H-chromen-3-yl)ethyl (4-chlorobenzyl)(p-tolyl)carbamodithioate(7s)*

Chemical Formula: C<sub>26</sub>H<sub>20</sub>ClNO<sub>3</sub>S<sub>2</sub> MS (*m/z*): 494.05 [M<sup>+</sup>]. <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.22-6.98 (m, 13H), 5.20 (s, 2H), 4.36 (s, 2H) 2.26 (s, 3H). <sup>13</sup>C NMR δ 193.84, 160.87, 154.25, 140.57, 136.67, 135.16, 132.90, 130.32, 129.74, 128.91, 128.18, 125.14, 122.58, 120.25, 118.12, 117.23, 55.78, 42.46, 22.92. Elemental Analysis: calculated C, 63.21; H, 4.08; N, 2.84% found C, 63.32; H, 4.01; N, 2.92%.


*2-Oxo-2-(2-oxo-2H-chromen-3-yl)ethyl (4-fluorobenzyl)(p-tolyl)carbamodithioate(7t)*

Chemical Formula: C<sub>26</sub>H<sub>20</sub>FNO<sub>3</sub>S<sub>2</sub> MS (*m/z*): 477.52 [M<sup>+</sup>]. <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.28-6.93 (m, 13H), 5.17 (s, 2H), 4.35 (s, 2H) 2.23 (s, 3H). <sup>13</sup>C NMR δ 193.94, 164.37, 161.53, 160.84, 154.17, 140.53, 136.40, 132.82, 131.69, 130.45, 129.68, 128.24, 125.18, 122.84, 120.76, 118.23, 117.27, 115.20, 114.71, 53.64, 42.52, 22.24. Elemental Analysis: calculated C, 65.39; H, 4.22; N, 2.93% found C, 65.25; H, 4.36; N, 2.83%.

## Results and Discussion

Using substituted aldehyde (**1a-d**) and substituted amine (**2a-e**) we prepared Schiff base (**3a-t**) with help of baker's yeast at room temperature<sup>4-5</sup>. Here we eliminate the conventional method of

synthesis of Schiff base and getting good result in 1<sup>st</sup> step. In 2<sup>nd</sup> step, reduction of Schiff base carried<sup>6</sup> out using sodium borohydride in methanol to obtained **4a-t**. Carbon disulfide and sodium hydroxide used for synthesis of carbodithiate derivatives (**5a-t**)<sup>7</sup>. Finally, active moiety 3-(bromoacetyl)-2*H*-chromen-2-one clubbed with **5a-t** using ethanol as a solvent to get desired product **7a-t** in good yield<sup>2,8</sup>. Detail experimental process is given below (Scheme 1).



A = ethanol, AcOH, B = NaBH<sub>4</sub>, H<sub>2</sub>O reflux, C = CS<sub>2</sub>, aq. NaOH, 0-5 °C, D = 6, ethanol, reflux, 6 hours

**Scheme 1**

### *Antibacterial activity*

The MICs of synthesized compounds were carried out by broth micro dilution method as described by Rattan<sup>9</sup>. Antibacterial activity (Table 2) was screened against gram positive and gram negative bacterial strain<sup>10-13</sup>.

Data of antibacterial activity shows that all compound **7a-t** are good to moderate active against gram positive and gram negative bacterial strains. More compounds are active against gram positive strains. Chemically we can classify that fluoro derivatives are potent to inhibit growth of bacterial strain *i.e.* compound **7d**, **7m**, **7o** and **7p** shows highest activity. Halogenated compound **7c** and **7k** are good while less substituted compound of the series not as effective as fluoro derivatives. So we carried out further antitubercular test for only active and fluorinated moiety.

### *Antitubercular activity*

*In vitro* antituberculosis activity of all the newly synthesized compounds against *Mycobacterium tuberculosis H37Rv* strain was determined by using Lowenstein-Jensen medium (conventional method) as described by Rattan<sup>9</sup> and the observed MIC of compounds are presented in Table 3.

Good results of antibacterial activity encourage us to go for Antitubercular activity and data are listed below. As per results we can say that only single fluorinated moiety is more active than di-fluoro compound and rest of compound are moderate against *M. Tuberculosis H37RV*. Thus, compound **7d** and **7m** are best compound of series.

**Table 2.** Antibacterial Activity (Minimal Inhibition Concentration, MIC,  $\mu\text{g/mL}$ )

S. No.	<i>E.c.</i> (-ve)	<i>P.a.</i> (-ve)	<i>Kl.pn.</i> (-ve)	<i>S.ty.</i> (-ve)	<i>S.a.</i> (+ve)	<i>S.py.</i> (+ve)	<i>B.s.</i> (+ve)
7a	500	500	500	500	500	500	500
7b	500	200	500	500	500	500	250
7c	100	500	500	250	62.5	62.5	200
7d	500	200	500	500	500	500	250
7e	500	500	500	500	500	500	500
7f	500	500	500	500	500	500	500
7g	500	500	500	500	500	500	500
7h	250	200	100	62.5	200	200	250
7i	500	500	500	500	500	500	500
7j	500	500	500	500	500	500	500
7k	250	200	200	250	100	200	100
7l	500	500	500	500	500	500	500
7m	200	200	250	250	200	200	200
7n	500	500	500	500	500	500	500
7o	100	200	200	250	100	100	100
7p	62.5	100	62.5	62.5	100	100	62.5
7q	500	500	500	500	200	500	500
7r	250	500	500	500	500	250	500
7s	500	250	250	500	500	500	500
7t	500	500	250	500	500	250	500
Gentamycin	0.05	1	0.05	1	0.25	0.5	0.5
Ampicillin	100	100	100	100	250	100	100
Chloramphenicol	50	50	50	50	50	50	50
Ciprofloxacin	25	25	25	25	50	50	50
Norfloxacin	10	10	10	10	10	10	10

*E.c.*=*E. Coli*(MTCC-443); *P.a.*=*P. Aeruginosa*(MTCC-1688); *Kl.pn.*=*Kl. Pneumoniae*(MTCC-109); *S.ty.*=*S. Typhi*(MTCC-98); *S.a.*=*S. Aureus*(MTCC-96); *S.py.*=*S. Pyogenus*(MTCC-442); *B.s.*=*B. Subtilis*(MTCC-441)

**Table 3.** Antitubercular Activity (Minimal Inhibition Concentration, MIC,  $\mu\text{g/mL}$ )

S. No	<i>M. tuberculosis H37RV</i>	% Inhibition
7c	500	98
7d	62.5	98
7h	500	98
7i	500	98
7k	1000	98
7m	50	99
7o	250	98
7p	250	99
Isoniazid	40	98
Rifampicin	0.20	99

*M. tuberculosis H37RV* (MTCC-200)

## Conclusion

In present study shows benefits of biocatalyst as well as new approach for synthesis can eliminate traditional and tedious synthesis protocol. Microbial study of presented

compounds is very interesting and fluoro derivative are hit molecules among the series and shows good antibacterial and antitubercular activity. Further investigation with appropriate structural modification and other activity carried out by our research team.

### Acknowledgment

We articulate our appreciation to authorities of V. P. & R. P. T. P. Science College, Sardar Patel University, Vallabh Vidyanagar (Gujarat, India) for providing infrastructural & chemical facilities. We are thankful to the Director, SICART, Vallabh Vidyanagar for spectral analysis facility. Authors are also grateful to the Microcare laboratory, Surat (Gujarat-India) for providing bioanalysis facility.

### References

1. Singh N G, Nongrum R, Kathing C, Star Rani J W and Nongkhaw R, *Green Chem Lett Rev.*, 2014, **7(2)**, 137-144; DOI:10.1080/17518253.2014.902506
2. Akhaja T N and Raval J P, *Med Chem Res.*, 2013, **22**, 4700-4707; DOI:10.1007/s00044-013-0472-0
3. Akhaja T N and Raval J P, *Eur J Med Chem.*, 2011, **46(11)**, 5573-5579; DOI:10.1016/j.ejmech.2011.09.023
4. Pratap U R, Jawale D V, Netankar P D and Mane R A, *Tet Let.*, 2011, **52(44)**, 5817-5819; DOI:10.1016/j.tetlet.2011.08.135
5. Pratap U R, Jawale D V, Bhosle M R and Mane R A, *Tet Let.*, 2011, **52(14)**, 1689-1691; DOI:10.1016/j.tetlet.2011.01.143
6. Billman J H and Diesing A C, *J Org. Chem.*, 1957, **22(9)**, 1068-1070; DOI:10.1021/jo01360a019
7. Feng L S, Liu M L, Wang B, Chai Y, Hao X Q, Meng S and Guo H Y, *Eur J Med Chem.*, 2010, **45(8)**, 3407-3412; DOI:10.1016/j.ejmech.2010.04.027
8. Gürsoy A, Ates Ö, Karali N, Cesur N and Kiraz M, *Eur J Med Chem.*, 1996, **31**, 643-646; DOI:10.1016/0223-5234(96)89561-4
9. Rattan A, *Antimicrobials in Laboratory Medicine*, Churchill B I, Livingstone, New Delhi, 2000, pp.85-108.
10. Sahu R and Shrivastava S P, *Chem Sci Trans.*, 2016, **5(2)**, 305-310; DOI:10.7598/cst2016.1190
11. Kateb B A, Hussien A K A, Kulkarni P A and Baseer M A, *Chem Sci Trans.*, 2016, **5(2)**, 353-360; DOI:10.7598/cst2016.1215
12. Karaarslan M, Koparir P, Cansiz A, Orek C and Sap O, *Chem Sci Trans.*, 2012, **1(1)**, 226-232; DOI:10.7598/cst2012.130
13. Kavitha R, Nagoor Meeran M and Sureshjeyakumar R P, *Chem Sci Trans.*, 2015, **4(4)**, 1001-1006; DOI:10.7598/cst2015.1118